Paula J. Andryuk

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 6 篇 · 总被引 1127 次 · h-index 6

代表论文

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (2006 · Clinical Therapeutics · 被引 516)
• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes (2009 · Diabetes Obesity and Metabolism · 被引 305)
• Three distinct human thymopoietins are derived from alternatively spliced mRNAs. (1994 · Proceedings of the National Academy of Sciences · 被引 111)
• Structure and Mapping of the Human Thymopoietin (TMPO) Gene and Relationship of Human TMPO β to Rat Lamin-Associated Polypeptide 2 (1995 · Genomics · 被引 88)
• Glucagon receptor antagonism induces increased cholesterol absorption (2015 · Journal of Lipid Research · 被引 77)
• Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor omarigliptin or the once‐daily DPP ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy (2017 · Diabetes Obesity and Metabolism · 被引 30)